FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

Source: 
Pharmaceutical Business Review
snippet: 


Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines.